Two red phosphorus (RP)-based smokes (P60 and RPB), differing from each other mainly in RP content and in type of additive, were evaluated for in vitro cytotoxicity (cell viability by the trypan-blue exclusion method) and genotoxicity (comet assay) by exposing BEAS 2B human bronchial epithelial cells to the smokes in a laboratory-scale chamber for 5 min. The irritation potency of RPB smoke was studied in mice. A hexachloroethane-based smoke (HC/Zn/TNT) was used as a reference in the studies. A 5-min exposure of BEAS 2B cells to P60 smoke (1.1, 2.2 and 4.4 g/m(3), measured as H(3)PO(4)) did not induce any cytotoxic effects, while RPB smoke (1.3, 2.6 and 5.1g/m(3), measured as H(3)PO(4)) caused a mild decrease in cell viability at higher concentrations, without a clear dose-dependent effect. Neither of the RP smokes showed a genotoxic response in the comet assay with BEAS 2B cells, while HC/Zn/TNT was clearly genotoxic (0.9-3.5 g/m(3) as ZnCl(2)). In the mouse bioassay, head-only exposure to RPB smoke (20-450 mg/m(3) for 30 min as a single exposure, or 65-90 and 25-110 mg/m(3) - measured as H(3)PO(4) - for 30 min/day during 5 days) caused a concentration-dependent sensory irritation, which was evident as a decrease in respiratory rate and an increase in time-of-pause after inspiration, in a similar manner as with HC/Zn/TNT smoke. The concentration that caused a 50% decrease in respiratory frequency (RD(max)50) was calculated to be 1140 mg/m(3) for the RPB smoke and 145 mg/m(3) for the HC/Zn/TNT smoke. No pulmonary irritation was observed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.mrgentox.2010.06.007 | DOI Listing |
Chronic Obstr Pulm Dis
September 2024
Weill Cornell Medicine, New York-Presbyterian Hospital, New York City, New York, United States.
Objective: We report mortality outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) among people with type 2 diabetes diagnosed within 10 years and no recent history of cardiovascular events or cancer.
Research Design And Methods: Overall mortality rates and major causes of death were assessed over an average of 5 years of follow-up. Cause of death was adjudicated centrally by a committee masked to treatment assignment.
Sci Rep
May 2023
Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.
Accelerated progression of chronic obstructive pulmonary disease (COPD) is associated with increased risks of hospitalization and death. Prognostic insights into mechanisms and markers of progression could facilitate development of disease-modifying therapies. Although individual biomarkers exhibit some predictive value, performance is modest and their univariate nature limits network-level insights.
View Article and Find Full Text PDFRespir Res
April 2023
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 15213, USA.
Flavored electronic cigarettes (ECs) present a serious health challenge globally. Currently, it is unknown whether the addition of highly popular menthol flavoring to e-liquid is associated with changes in the number of aerosolized particles generated or altered lung function. Here, we first performed preclinical studies using our novel robotic platform Human Vaping Mimetic Real-Time Particle Analyzer (HUMITIPAA).
View Article and Find Full Text PDFAm J Physiol Lung Cell Mol Physiol
January 2023
Marsico Lung Institute, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Nicotine from cigarette smoke is a biologically active molecule that has pleiotropic effects in the airway, which could play a role in smoking-induced lung disease. However, whether nicotine and its metabolites reach sustained, physiologically relevant concentrations on airway surfaces of smokers is not well defined. To address these issues, concentrations of nicotine, cotinine, and hydroxycotinine were measured by mass spectrometry (MS) in supernatants of induced sputum obtained from participants in the subpopulations and intermediate outcome measures in COPD study (SPIROMICS), an ongoing observational study that included never smokers, former smokers, and current smokers with and without chronic obstructive pulmonary disease (COPD).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!